Clinical pharmacology of GP53,633--a new non-steroidal anti-inflammatory drug--in patients with rheumatoid arthritis.
GP53,633 is a new basic non-steroidal anti-inflammatory drug showing analgesic and anti-inflammatory activity in animal models. Pharmacokinetic studies in 6 patients with rheumatoid arthritis show it to be rapidly absorbed with a short half life (approximately 2 hours). No change in pharmacokinetics is seen over a two week treatment period. Clinical parameters of inflammation were reduced and no adverse reactions were seen.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000378:metabolism*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000378:metabolism*; D006207:Half-Life; D006801:Humans; D007093:Imidazoles / Q000378:metabolism* / Q000627:therapeutic use; D007700:Kinetics; D008875:Middle Aged
D000893:Anti-Inflammatory Agents; D007093:Imidazoles; C036844:2-tert-butyl-4(5)-phenyl-5(4)-(3-pyridyl)imidazole